Activation of p53 in Malignant Mesothelioma

被引：0
|
作者：
Singh, Anand [1 ]
Bhattacharyya, Nisan [1 ]
Srivastava, Abhishek [2 ]
Zhang, Li [1 ]
Schrump, David [1 ]
Hoang, Chuong [1 ]
机构：
[1] NCI, Thorac & Gi Oncol Branch, Bethesda, MD 20892 USA
[2] NCI, Surg Branch, Bethesda, MD 20892 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Mesothelioma; p53; tumor suppressor;
D O I：
10.1016/j.jtho.2016.11.1909
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.03-010
引用
收藏
页码：S1349 / S1350
页数：2
相关论文
共 50 条
  • [1] Resveratrol contributes to chemosensitivity of malignant mesothelioma cells with activation of p53
    Lee, Yoon-Jin
    Park, Ihl-Sung
    Lee, Yong-Jin
    Shim, Jung-Hyun
    Cho, Moon-Kyum
    Nam, Hae-Seon
    Park, Ji Woong
    Oh, Myung-Ho
    Lee, Sang-Han
    FOOD AND CHEMICAL TOXICOLOGY, 2014, 63 : 153 - 160
  • [2] P53 EXPRESSION IS COMMON IN MALIGNANT MESOTHELIOMA
    KAFIRI, G
    THOMAS, DM
    SHEPHERD, NA
    KRAUSZ, T
    LANE, DP
    HALL, PA
    HISTOPATHOLOGY, 1992, 21 (04) : 331 - 334
  • [3] IMMUNOREACTIVITY FOR P53 PROTEIN IN MALIGNANT MESOTHELIOMA AND NONNEOPLASTIC MESOTHELIUM
    RAMAEL, M
    LEMMENS, G
    EERDEKENS, C
    BUYSSE, C
    DEBLIER, I
    JACOBS, W
    VANMARCK, E
    JOURNAL OF PATHOLOGY, 1992, 168 (04): : 371 - 375
  • [4] Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma
    Segers, K
    Backhovens, H
    Kumar-Singh, S
    DeVoecht, J
    Ramael, M
    Van Broeckhoven, C
    VanMarck, E
    VIRCHOWS ARCHIV, 1995, 427 (04) : 431 - 436
  • [5] Mutations in the P53 tumor suppressor gene in human malignant mesothelioma
    Appasani, K
    Fournier, MV
    Sugarbaker, DJ
    Pardee, AB
    Bueno, R
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A212 - A212
  • [6] p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
    J Creaney
    B M McLaren
    S Stevenson
    A W Musk
    N de Klerk
    B W S Robinson
    R A Lake
    British Journal of Cancer, 2001, 84 : 52 - 56
  • [7] p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression
    Creaney, J
    McLaren, BM
    Stevenson, S
    Musk, AW
    de Klerk, N
    Robinson, BWS
    Lake, RA
    BRITISH JOURNAL OF CANCER, 2001, 84 (01) : 52 - 56
  • [8] P16 and p53 protein expression in malignant mesothelioma and mesothelial proliferative processes
    Valladares, M.
    Lujan, D. R.
    Avila, R.
    Santos, A.
    Gomez, L.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 244 - 244
  • [9] Pharmacological Targeting of p53 Effectively Induces Apoptosis in Malignant Mesothelioma Cell Lines
    Di Marzo, D.
    Forte, I. M.
    Indovina, P.
    Di Gennaro, E.
    Giorgi, F.
    Rizzo, V.
    Mattioli, E.
    Budillon, A.
    Giordano, A.
    Pentimalli, F.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S255 - S255
  • [10] The MDM2/p53 Axis is a Therapeutic Vulnerability in Malignant Pleural Mesothelioma
    Heasley, L.
    Hinz, T.
    Pacheco, J.
    Tirunagaru, V.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S955 - S955
12345